of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.protriptylinetrifluoperazine and protriptyline both increase sedation. Use Caution/Monitor.pseudoephedrinetrifluoperazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.quazepamquazepam and trifluoperazine both increase sedation. Use Caution/Monitor.quetiapinequetiapine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.quetiapine and trifluoperazine both increase sedation. Use Caution/Monitor.quinidinequinidine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.ramelteontrifluoperazine and ramelteon both increase sedation. Use Caution/Monitor.ranolazinetrifluoperazine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.rapacuroniumrapacuronium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.rapacuronium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of rapacuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.remimazolamremimazolam, trifluoperazine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.rimabotulinumtoxinBtrifluoperazine, rimabotulinumtoxinB. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Anticholinergics may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.risperidonerisperidone and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.trifluoperazine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.risperidone and trifluoperazine both increase sedation. Use Caution/Monitor.rizatriptanrizatriptan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).rocuroniumrocuronium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.rocuronium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of rocuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.romidepsintrifluoperazine and romidepsin both increase QTc interval. Modify Therapy/Monitor Closely.rucaparibrucaparib will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP1A2 substrates, if clinically indicated.salmeteroltrifluoperazine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.scopolaminescopolamine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.scopolamine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of scopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.scullcaptrifluoperazine and scullcap both increase sedation. Use Caution/Monitor.secobarbitalsecobarbital and trifluoperazine both increase sedation. Use Caution/Monitor.selegilineselegiline, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).serdexmethylphenidate/dexmethylphenidatetrifluoperazine, serdexmethylphenidate/dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.sertralinesertraline and trifluoperazine both decrease QTc interval. Use Caution/Monitor.sevofluranesevoflurane and trifluoperazine both increase sedation. Use Caution/Monitor.sevoflurane and trifluoperazine both decrease QTc interval. Use Caution/Monitor.shepherd's pursetrifluoperazine and shepherd's purse both increase sedation. Use Caution/Monitor.siponimodsiponimod and trifluoperazine both decrease QTc interval. Use Caution/Monitor.smokingsmoking decreases levels of trifluoperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.sodium sulfate/?magnesium sulfate/potassium chloridesodium sulfate/?magnesium sulfate/potassium chloride increases effects of trifluoperazine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of enhanced CNS depression when using higher dose of magnesium sulfate together with a CNS depressant.sodium sulfate/potassium sulfate/magnesium sulfatesodium sulfate/potassium sulfate/magnesium sulfate increases effects of trifluoperazine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of enhanced CNS depression when using higher dose of magnesium sulfate together with a CNS depressant.solifenacinsolifenacin decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.solifenacin and trifluoperazine both decrease QTc interval. Use Caution/Monitor.stiripentolstiripentol, trifluoperazine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP1A2 inhibitor and inducer. Monitor CYP1A2 substrates coadministered with stiripentol for increased or decreased effects. CYP1A2 substrates may require dosage adjustment.sufentanilsufentanil and trifluoperazine both increase sedation. Use Caution/Monitor.sulfamethoxazoletrifluoperazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.sumatriptansumatriptan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).sumatriptan intranasalsumatriptan intranasal, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).sunitinibsunitinib and trifluoperazine both decrease QTc interval. Use Caution/Monitor.tacrolimustacrolimus and trifluoperazine both decrease QTc interval. Use Caution/Monitor.tapentadoltapentadol and trifluoperazine both increase sedation. Use Caution/Monitor.teduglutideteduglutide increases levels of trifluoperazine by Other (see comment). Use Caution/Monitor. Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.telavancintrifluoperazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.temazepamtemazepam and trifluoperazine both increase sedation. Use Caution/Monitor.terbutalinetrifluoperazine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.teriflunomideteriflunomide decreases levels of trifluoperazine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.tetrabenazinetrifluoperazine and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.thioridazinethioridazine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.thioridazine and trifluoperazine both increase sedation. Use Caution/Monitor.thiothixenethiothixene and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.thiothixene and trifluoperazine both increase sedation. Use Caution/Monitor.tiotropiumtiotropium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.tiotropium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.tobacco usetobacco use decreases levels of trifluoperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.tolterodinetolterodine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.tolterodine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.topiramatetrifluoperazine and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadoltramadol and trifluoperazine both increase sedation. Use Caution/Monitor.tranylcyprominetranylcypromine, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).trazodonetrifluoperazine and trazodone both increase sedation. Use Caution/Monitor.triazolamtriazolam and trifluoperazine both increase sedation. Use Caution/Monitor.triclofostriclofos and trifluoperazine both increase sedation. Use Caution/Monitor.trihexyphenidyltrihexyphenidyl decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive anticholinergic effects.trimethoprimtrifluoperazine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.trimipraminetrifluoperazine and trimipramine both increase sedation. Use Caution/Monitor.triprolidinetriprolidine and trifluoperazine both increase sedation. Use Caution/Monitor.tropisetrontrifluoperazine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.trospium chloridetrospium chloride decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.trospium chloride decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of trospium chloride by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.valbenazinevalbenazine and trifluoperazine both decrease QTc interval. Use Caution/Monitor.vecuroniumvecuronium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.vecuronium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.venlafaxinevenlafaxine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.trifluoperazine and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.venlafaxine, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).vilazodonevilazodone, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).voriconazoletrifluoperazine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.vorinostatvorinostat and trifluoperazine both decrease QTc interval. Use Caution/Monitor.xylometazolinetrifluoperazine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, xylometazoline. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.yohimbinetrifluoperazine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, yohimbine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.ziconotidetrifluoperazine and ziconotide both increase sedation. Use Caution/Monitor.ziprasidonetrifluoperazine and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.trifluoperazine and ziprasidone both increase sedation. Use Caution/Monitor.zolmitriptanzolmitriptan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).zolpidemtrifluoperazine will increase the level or effect of zolpidem by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Additive effect of decreased alertness and psychomotor performancezotepinetrifluoperazine and zotepine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.trifluoperazine and zotepine both increase sedation. Use Caution/Monitor.Minor (61)amiodaroneamiodarone will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.amitriptylineamitriptyline, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amitriptyline, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.amoxapineamoxapine, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amoxapine, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.asenapineasenapine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.atropinetrifluoperazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMtrifluoperazine increases toxicity of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.benazepriltrifluoperazine increases effects of benazepril by unspecified interaction mechanism. Minor/Significance Unknown. Enhanced hypotensive effects.brimonidinebrimonidine increases effects of trifluoperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.bupropiontrifluoperazine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible.captopriltrifluoperazine increases effects of captopril by unspecified interaction mechanism. Minor/Significance Unknown. Both drugs lower blood pressure. Monitor blood pressure.celecoxibcelecoxib will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.chasteberrychasteberry decreases effects of trifluoperazine by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction).chloroquinechloroquine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.chloroquine increases levels of trifluoperazine by decreasing metabolism. Minor/Significance Unknown.cimetidinecimetidine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.clomipramineclomipramine, trifluoperazine. Either increases levels of the other by